AstraZeneca Is Tougher Target for Possible New Pfizer Bid

Pfizer Inc. isn’t giving up on striking an overseas takeover to cut its tax rate and gain a new pipeline of drugs, even as the potential cost of acquiring AstraZeneca Plc rises.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.